Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
23.60
-0.10 (-0.42%)
Apr 16, 2026, 3:58 PM EDT - Market open
Arcus Biosciences Employees
Arcus Biosciences had 601 employees as of December 31, 2025. The number of employees decreased by 26 or -4.15% compared to the previous year.
Employees
601
Change (1Y)
-26
Growth (1Y)
-4.15%
Revenue / Employee
$410,982
Profits / Employee
-$587,354
Market Cap
2.96B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 601 | -26 | -4.15% |
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 511 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Alumis | 224 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Disc Medicine | 155 |
| IDEAYA Biosciences | 145 |
RCUS News
- 6 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 weeks ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 7 weeks ago - Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer - Business Wire
- 2 months ago - Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates - Business Wire
- 3 months ago - Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs - Business Wire
- 4 months ago - Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga